55904-12-6

Basic information

• Product Name: 1,3-Dioxolane-4,5-dimethanol, 2,2-dimethyl-, cis-
• CAS NO: 55904-12-6
• Molecular Formula: C7H14O4
• Molecular Weight: 162.186
• Mol File: 55904-12-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1,3-Dioxolane-4,5-dimethanol, 2,2-dimethyl-, cis-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dioxolane-4,5-dimethanol, 2,2-dimethyl-, cis-(55904-12-6)
• EPA Substance Registry System: 1,3-Dioxolane-4,5-dimethanol, 2,2-dimethyl-, cis-(55904-12-6)

Safety Data

• Hazardous Substances Data: 55904-12-6(Hazardous Substances Data)

Usage

Description

1,3-Dioxolane-4,5-dimethanol, 2,2-dimethyl-, cisis a unique organic compound characterized by its specific molecular structure, which features a 1,3-dioxolane ring with two methyl groups at the 2,2-positions and a cis-configuration. 1,3-Dioxolane-4,5-dimethanol, 2,2-dimethyl-, cispossesses hydroxy radical-scavenging properties, making it a valuable ingredient in various applications.

Uses

Used in Cosmetic Industry:
1,3-Dioxolane-4,5-dimethanol, 2,2-dimethyl-, cisis used as an active ingredient in cosmetic creams for its hydroxy radical-scavenging effect. This property helps protect the skin from oxidative stress and contributes to maintaining skin health and appearance.
Used in Food and Beverage Industry:
In the food and beverage industry, 1,3-Dioxolane-4,5-dimethanol, 2,2-dimethyl-, cisis used in the preparation of fruit beverages. Its hydroxy radical-scavenging effect helps to preserve the quality and freshness of the beverages, ensuring a longer shelf life and better taste.
These applications highlight the versatility of 1,3-Dioxolane-4,5-dimethanol, 2,2-dimethyl-, cisas a compound with potential benefits in both personal care and food products. Its ability to scavenge hydroxy radicals makes it a valuable asset in formulating products that promote health and longevity.

Upstream product

• 116499-08-2 dimethyl 2,2-dimethyl-1,3-dioxolane-trans-4,5-dicarboxylate 

Downstream Products

• 1256911-58-6 (2S,3R,4R,5R)-2-benzyloxymethyl-3,4-isopropylidenedioxy-5-methoxytetrahydrofuran 
• 29325-28-8 (3aR,4R,6R,6aR)-4-methoxy-2,2-dimethyl-6-vinyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole 
• 5531-21-5 (2S,3R,4R,5R)-(3,4-isopropylidenedioxy-5-methoxy-2-tetrahydrofuranyl)methanol 
• 35906-38-8 (2S,3R,4R,5R)-3,4-isopropylidenedioxy-5-methoxy-2-vinyltetrahydrofuran 
• 33019-63-5 (2R,3R,4R,5R)-2-benzyloxymethyl-3,4-isopropylidenedioxy-5-methoxytetrahydrofuran 
• 4099-85-8 ((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 
• 85624-09-5 (3aR,9R,9aR,9bS)-octahydro-2,2-dimethyl-[1,3]dioxolo[4,5-a]indolizin-9-ol 
• 4248-74-2 2,3-O-Isopropyliden-DL-threitol-1,4-bis-methansulfonat 
• 71806-86-5 (4R,5S)-4,5-bis((benzyloxy)methyl)-2,2-dimethyl-1,3-dioxolane 
• 1357623-17-6 C₂₂H₂₉BrN₂O₈ 
• 1357622-97-9 C₂₉H₃₆BrN₃O₈ 
• 1357622-92-4 C₂₅H₂₈Br₂N₂O₆ 
• 1357622-86-6 C₂₅H₃₅BrN₂O₆ 
• 1357622-83-3 C₂₁H₂₉BrN₂O₇ 

Relevant articles and documents

Combination of chemotherapy and oxidative stress to enhance cancer cell apoptosis

Cancer cells are vulnerable to reactive oxygen species (ROS) due to their abnormal redox environment. Accordingly, combination of chemotherapy and oxidative stress has gained increasing interest for the treatment of cancer. We report a novel seleno-prodrug of gemcitabine (Gem), Se-Gem, and evaluated its activation and biological effects in cancer cells. Se-Gem was prepared by introducing a 1,2-diselenolane (a five-membered cyclic diselenide) moiety into the parent drug Gemvia a carbamate linker. Se-Gem is preferably activated by glutathione (GSH) and displays a remarkably higher potency than Gem (up to a 6-fold increase) to a panel of cancer cell lines. The activation of Se-Gem by GSH releases Gem and a seleno-intermediate nearly quantitatively. Unlike the most ignored side products in prodrug activation, the seleno-intermediate further catalyzes a conversion of GSH and oxygen to GSSG (oxidized GSH) and ROS via redox cycling reactions. Thus Se-Gem may be considered as a suicide agent to deplete GSH and works by a combination of chemotherapy and oxidative stress. This is the first case that employs a cyclic diselenide in prodrug design, and the success of Se-Gem as well as its well-defined action mechanism demonstrates that the 1,2-diselenolane moiety may serve as a general scaffold to advance constructing novel therapeutic molecules with improved potency via a combination of chemotherapy and oxidative stress.

1,4-BISMETHANESULFONATES OF THE STEREOISOMERIC BUTANETETRAOLS AND

-